INTRODUCTION

I
nvestigators involved in heart-brain medicine are dedicated to defi ning the physiology associated with interactions of the neurological and cardiovascular systems. In 2004 the Bakken Heart-Brain Institute was founded at Cleveland Clinic because we believed that furthering our understanding of this physiology could lead to a better understanding of chronic disease, defi ne novel therapies, and improve patient outcomes.
The 2008 Bakken Heart-Brain Summit, held last June in Cleveland, further demonstrated real progress in our understanding of the importance of heart-brain interactions in health and disease. The opening session of the 2008 Summit focused on reviewing the evidence linking psychiatric disorders-specifi cally depression-to increased infl ammation and plaque rupture associated with worsening outcomes in patients with atherosclerotic heart disease. These pathways linking psychiatric disorders to acute coronary syndrome were proposed after the 2007 Bakken Heart-Brain Summit (Figure 1) 1 : Depression leads to decreased vagal tone • Decreased vagal tone leads to increased infl ammation • Increased infl ammation leads to acute coronary • syndrome.
Speakers at the 2008 Summit offered insights into the physiology, clinical measures, and molecular pathways involved in linking the heart and the brain, including:
Measures of heart rate variability in depression • The utility of heart rate variability and heart • rate recovery in quantifying vagal tone and outcome in patients with and without coronary artery disease Pathways of infl ammation involved in acute • coronary syndrome. The studies published since June 2008 demonstrate clear links between depression and morbidity and mortality from cardiovascular causes. A recent paper from the Nurses' Health Study showed that individuals with depression had a higher incidence of cardiovascular death. 3 Notably, subjects in the Nurses' Health Study had no clinical evidence of atherosclerotic heart disease at enrollment. In another recent study, depression was associated with worse outcomes in patients following coronary stenting. 4 Finally, and most interestingly, depression was recently associated with endothelial dysfunction in patients with atypical angina and angiographically normal coronary arteries. 5 Thus, regardless of the degree of underlying atherosclerosis, depression is associated with cardiovascular morbidity or mortality.
MOUNTING CLINICAL EVIDENCE LINKING DEPRESSION WITH CARDIAC OUTCOMES
Less clear is the relationship between depression and infl ammation as measured by surrogate infl ammatory markers. An analysis of the Canadian Nova Scotia Health Survey [NSHS95] Prospective Population Study suggested that increased infl ammatory markers accounted for only a small portion of the risk of coronary heart disease associated with depression. 6 Conversely, a recent analysis of patients with stable coronary artery disease demonstrated a strong correlation between major depressive disorders and highsensitivity C-reactive protein. 7 Clearly, signifi cant work has yet to be done to fully elucidate the molecular pathways that link depression and adverse outcomes in patients at risk for coronary artery disease. That said, it is very encouraging that professional societies are beginning to recognize the value and importance of heart-brain medicine in identifying novel strategies for improving patient outcomes.
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STILL ELUSIVE: EVIDENCE THAT DEPRESSION THERAPY IMPROVES CARDIAC OUTCOMES
At the 2008 Summit there was clear enthusiasm among attendees and faculty for advances in our understanding of the pathways discussed above. Since then, as reviewed above, signifi cant publications have furthered the link between heart and brain in the setting of atherosclerotic heart disease. That said, the missing piece-the demonstration that treating depression leads to improved outcomes in patients with coronary artery disease-remains missing.
Some advances in this regard have been made. A recent study from the Enhancing Recovery In Coronary Heart Disease (ENRICHD) clinical trial demonstrated that major depression in any patient who survived myocardial infarction decreased survival over 2.5 years. 8 Interestingly, and perhaps critical for an event-driven treatment trial in the future, this analysis showed an even worse outcome in patients who experienced their initial episode of major depression after their myocardial infarction. 8 The need, ethics, and design of clinical trials to determine whether treatment of depression leads to improved outcomes in patients with coronary artery disease will be a major topic of the 4th Annual Heart-Brain Summit, to be held in Chicago on October 15-16, 2009.
OTHER HIGHLIGHTS, INCLUDING ROLE OF THE HEALING ENVIRONMENT
While much of the early focus of the 2008 HeartBrain Summit was on the interaction of depression, infl ammation, and outcomes in patients with coronary artery disease, a signifi cant portion of the Summit identifi ed other disease states and opportunities. The disease states discussed can be divided into primary cardiac, primary psychiatric, and primary neurologic. Cardiac topics under continued investigation include the role of vagal tone on the infl ammatory response that regulates left ventricular remodeling following acute myocardial infarction 9 as well as the role of spinal stimulation for treatment of refractory myocardial ischemia. Psychiatric disorders of interest that have been shown to modulate vagal tone include post-traumatic stress disorder, 10 which has also been shown to increase the risk for coronary heart disease. 11, 12 Neurologically, advances concerning the polyvagal theory of autonomic nervous system control and cardiac control were discussed. 13, 14 On the Summit's fi nal day, the discussions of neuropathways, infl ammation, and cardiac control gave way to presentations on the role of the healing environment. Following discussions of how depression can have signifi cant ramifi cations on systemic infl ammation and acute coronary syndrome, it was interesting to review data on how the presence of family and the patient environment can improve patient outcomes.
Many of the topics touched on above are discussed in greater detail in the following pages of this proceedings of the 2008 Bakken Heart-Brain Summit. We are gratifi ed to see the advancements in the fi eld of heartbrain medicine over the past 5 years, and especially to see the recognition the discipline is receiving in our attempt to improve patient outcomes.
FAR MORE QUESTIONS REMAIN
Without a doubt there are more questions than answers at this time. That said, by continuing the rigorous multidisciplinary approach that has served this 
